Abstracts tagged "outcomes and vasculitis"

Abstract Number: 2717 • 2017 ACR/ARHP Annual Meeting
Late Onset of IgA Vasculitis Is Associated with More Severe Renal Involvement
Alexandra Audemard-Verger¹, Aurélie Baldolli², Noemie Le Gouellec³, Loic Raffray⁴, Alban Deroux⁵, Julie Goutte⁶, Bertrand Lioger⁷, Zahir Amoura⁸, Patrice Cacoub⁹, Sébastien Sanges¹⁰, Evangeline Pillebout¹¹, Loïc Guillevin for the French Vasculitis Study Group¹² and Benjamin Terrier¹³, ¹Internal Medicine, Caen, France, ²Internal Medicine, CHU, Caen, France, ³Internal Medicine, Lille, France, ⁴Internal Medicine, CHU de Bordeaux, Bordeaux, France, ⁵Internal Medicine, CHU de Grenoble, Grenoble, France, ⁶Internal Medicine, Saint Etienne, France, ⁷GICC UMR 7292, University François Rabelais, Tours, France, ⁸Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁹Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ¹⁰Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ¹¹Nephrology, Saint Louis, Paris, France, ¹²Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ¹³Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: Immunoglobulin A vasculitis (IgAV), formerly called Henoch–Schönlein purpura, is a small-vessel vasculitis characterized by immune-complex deposits with predominant IgA. Although the disease is often…
Abstract Number: 126 • 2016 ACR/ARHP Annual Meeting
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in African-American Patients: Disease Associations and Clinical Outcomes in an Urban Cohort
Philip McCarthy¹, Jenna Hudy², Marie Melville², Danielle Robson¹, John McKinnon², Sandeep Soman² and Kathleen Maksimowicz-McKinnon³, ¹Michigan State University College of Osteopathic Medicine, East Lansing, MI, ²Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) has been most extensively described and studied in non-African-American populations. The significance of and associations with ANCA in African-Americans,…
Abstract Number: 127 • 2016 ACR/ARHP Annual Meeting
Disease Characteristics and Outcomes in African-American Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: a High Risk Group for Poor Outcomes
Philip McCarthy¹, Danielle Robson¹, Jenna Hudy², Marie Melville², John McKinnon², Sandeep Soman² and Kathleen Maksimowicz-McKinnon³, ¹Michigan State University College of Osteopathic Medicine, East Lansing, MI, ²Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Antineutrophil antibody-associated vasculitis (AAV) has been most extensively described and studied in non-African American populations. Little is known about the characteristics and outcomes of…
Abstract Number: 1000 • 2016 ACR/ARHP Annual Meeting
Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases
John McKinnon¹, Junying Zhou², Jenna Hudy¹, Sara Hegab¹ and Kathleen Maksimowicz-McKinnon³, ¹Henry Ford Hospital, Detroit, MI, ²Infectious Diseases, Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Both subclinical cytomegalovirus (CMV) viremia and CMV disease have been associated with adverse outcomes in select immunosuppressed populations, including an increased incidence of other…
Abstract Number: 1943 • 2016 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse
Maxime Samson¹, Hervé Devilliers², Xavier Puéchal³, Christian Pagnoux⁴, Pascal Cohen³, Luc Mouthon³, Benjamin Terrier⁵ and Loïc Guillevin³, ¹Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: To identify associations between patients’ clinical and biological characteristics at diagnosis of antineutrophil cytoplasmic antibody-associated vasculitides (AAVs), and their relapse during follow-up. Methods: Long-term…
Abstract Number: 1953 • 2016 ACR/ARHP Annual Meeting
Management and Outcomes of ANCA-Associated Vasculitis in Unselected Cases within a Large Health Region of England
Fiona Pearce¹, Catherine McGrath², Ravinder Sandhu³, Jon Packham⁴, Karen Obrenovich⁵, Richard A. Watts⁶, Peter Lanyon⁷ and for the East Midlands, West Midlands and East of England regional audit groups, ¹Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom, ²Department of Rheumatology, The Dudley Group NHS Foundation Trust, Dudley, United Kingdom, ³The Dudley Group NHS Foundation Trust, Dudley, Great Britain, ⁴University of Keele, Keele, United Kingdom, ⁵The Dudley Group NHS Foundation Trust, Dudley, United Kingdom, ⁶Rheumatology Department, Ipswich Hospital, Ipswich, Great Britain, ⁷Department of Rheumatology, Nottingham University Hospitals NHS trust, Nottingham, United Kingdom
Background/Purpose: Most data on management and outcomes of ANCA-associated vasculitis (AAV) come from highly selected populations in tertiary referral centres, or clinical trials. These results…
Abstract Number: 1954 • 2016 ACR/ARHP Annual Meeting
Clinical Features and Long Term Outcome of 105 Patients of Granulomatosis with Polyangiitis: A Single Centre Experience from North India
Aman Sharma¹, Shankar Naidu², Manish Rathi³, Benzeeta Pinto⁴, Kusum Sharma⁵, Varun Dhir⁶, Ritambhra Nada⁷, Ranjana Minz⁸ and Surjit Singh⁹, ¹Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, cHANDIGARH, India, ³Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁴PGIMER, CHANDIGARH, India, ⁵Department of Medical Microbiology,, PGIMER,, Chandigarh, India, ⁶Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ⁷Histopathology, Professor, Chandigarh, India, ⁸Department of Immunopathology,, PGIMER,, Chandigarh, India, ⁹Department of Internal Medicine,, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: The published Indian data on Granulomatosis with Polyangiitis (GPA) is sparse and only in the form of few small case series. The purpose of this study…
Abstract Number: 2856 • 2014 ACR/ARHP Annual Meeting
Update on Long-Term Outcomes after Reversible Cerebral Vasoconstriction Syndrome (RCVS)
Seby John¹, Aneesh Singhal², Leonard H. Calabrese³, Ken Uchino⁴, Tariq Hammad³, Stewart Tepper³, Mark Stillman³ and Rula A Hajj-Ali⁵, ¹9500 Euclid Avenue S10-C, Cleveland Clinic Foundation, Cleveland, OH, ²Neurology, Massachusetts General Hospital, Boston, MA, ³Cleveland Clinic Foundation, Cleveland, OH, ⁴Neurology, Cleveland Clinic Foundation, Cleveland, OH, ⁵Rheumatology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose RCVS is characterized by acute onset of severe headaches, with or without neurologic deficit with evidence of reversible cerebral vasoconstriction. We have previously reported…
Abstract Number: 1781 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcomes Among Patients with Renal Disease Secondary to ANCA-Associated Vasculitis: Temporal Trends over 25 Years
Rennie L. Rhee¹, Susan L Hogan², Caroline J. Poulton², Julie Anne G. McGregor², J. Richard Landis³, Ronald Falk⁴ and Peter A. Merkel⁵, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²UNC Kidney Center, Chapel Hill, NC, ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Dept of Nephrology and Hypertension, UNC Kidney Center, Chapel Hill, NC, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose Significant advances have been made in the diagnosis and treatment of patients with ANCA-associated vasculitis (AAV). However, little is known about how these advances…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].